Loading cancer entity…
Loading cancer entity…
Clinical trials
181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | recruiting | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07722611 | A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) | recruiting | Phase 2 / Phase 3 | 380 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | recruiting | Phase 2 | 25 | University of WashingtonOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07648030 | A Study of Rusfertide in Japanese Adults With Polycythemia Vera | recruiting | Phase 2 | 9 | TakedaINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07232290 | Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | recruiting | Phase 2 | 60 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06063486 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | recruiting | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05123365 | An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms | recruiting | Phase 1 / Phase 2 | 27 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04644211 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial(TREATMORE) | recruiting | Phase 2 | 54 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials